<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00357539</url>
  </required_header>
  <id_info>
    <org_study_id>LT1225-PI1-09/01(F)</org_study_id>
    <nct_id>NCT00357539</nct_id>
  </id_info>
  <brief_title>Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers</brief_title>
  <official_title>Comparison of the Ocular Tolerance, the Safety and the Ocular Pharmacokinetics After One Drop of Three Different Concentrations of T1225 (0.5% - 1.0% - 1.5%) in 48 Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Thea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Thea</source>
  <brief_summary>
    <textblock>
      To compare the ocular tolerance, safety and ocular pharmacokinetics of 3 concentrations (0.5%
      - 1.0% - 1.5%) and the vehicle of T1225.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present phase I clinical trial was performed in order to investigate the ocular
      tolerance, safety and the ocular pharmacokinetics of a single administration of T1225 eye
      drops (0.5%, 1.0%, or 1.5%) in healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date>March 2002</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective ocular symptoms</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective ocular symptoms</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular pharmacokinetic</measure>
  </secondary_outcome>
  <condition>Eye Infections, Bacterial</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin (T1225)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged from 18 to 45 years old;

          -  Written informed consent;

          -  Healthy volunteers (without any ocular symptom);

          -  Normal ocular examination in both eyes (corrected visual acuity (VA) &gt;= 6/10 - slit
             lamp examination without clinical relevant abnormalities - tear break-up time (BUT) &gt;=
             10 seconds - lachrymal secretion in the Schirmer test &gt;= 10 mm in 5 minutes -
             lissamine green test total score &lt; 4).

        Exclusion Criteria:

          -  Ocular trauma, infection or inflammation within the last 3 months;

          -  Conjunctival hyperaemia score &gt;= 2, watering score &gt;= 2, folliculo-papillary
             conjunctivitis score &gt;= 2, number of fluorescein-stained punctuations &gt;= 10;

          -  Blepharitis, conjunctivitis, uveitis;

          -  Ocular laser treatment within the last 3 months;

          -  Ocular surgery, including LASIK and PRK, within the last 12 months;

          -  Topical ocular treatment during the last month;

          -  Ocular antibiotics within the last 7 days;

          -  Medication during the study (except paracetamol and contraceptives).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claude DUBRAY, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unité de Pharmacologie Clinique - Clermont-Ferrand (France)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unité de Pharmacologie Clinique</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2006</study_first_submitted>
  <study_first_submitted_qc>July 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2006</study_first_posted>
  <last_update_submitted>July 26, 2006</last_update_submitted>
  <last_update_submitted_qc>July 26, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Eye Infections</mesh_term>
    <mesh_term>Eye Infections, Bacterial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

